Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SCH 465981, ezetimibe, simvastatin, niacin, nicotinic acid
Vytorin+ Niaspan · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Vytorin + Niaspan | EXPERIMENTAL | NIASPAN 1000 mg (1 x 1000 mg tablet) once-daily in the morning on Days 1 to 2, followed by NIASPAN 2000 mg (2 x 1000 mg tablets) once-daily in the morning on Days 3 to 7 + VYTORIN 10/20 mg (1 x 10/20 mg tablet containing ezetimibe 10 mg and simvastatin 20 mg) once-daily in the morning for 7 days |
| Vytorin | ACTIVE_COMPARATOR | VYTORIN 10/20 mg (1 x 10/20 mg tablet containing ezetimibe 10 mg and simvastatin 20 mg) once-daily in the morning for 7 days |
| Niaspan | ACTIVE_COMPARATOR | NIASPAN 1000 mg (1 x 1000 mg tablet) once-daily in the morning on Days 1 to 2, followed by NIASPAN 2000 mg (2 x 1000 mg tablets) once-daily in the morning on Days 3 to 7 for a total of 7 days of treatment |
| Name | Type | Description |
|---|---|---|
| Vytorin + Niaspan | DRUG | Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days + Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7 |
| Vytorin | DRUG | Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days |
| Niaspan | DRUG | Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7 |
Inclusion Criteria: The subject must meet ALL the criteria listed below for entry: * Subjects must be willing to give written informed consent and able to adhere to dose and visit schedules. * Subjects of either sex and of any race between the ages of 18 and 55 years, inclusive, having a Body Mass...
Top 12 of 15 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 4 | PHASE3 | Enlicitide |
| Novartis AG Sponsored ADR | NVS | 14 | PHASE3 | Inclisiran, Pelacarsen, DII235, QCZ484 |
| AstraZeneca PLC | AZN | 3 | PHASE3 | AZD0780, Laroprovstat, Rosuvastatin |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 5 | PHASE3 | Plozasiran, zodasiran, VSA003 |
| Ionis Pharmaceuticals, Inc. | IONS | 2 | PHASE3 | Olezarsen, ION775 |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE2 | Alirocumab |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Solbinsiran |
| MediciNova, Inc. | MNOV | 1 | PHASE2 | MN-001 |
| Verve Therapeutics, Inc. | VERV | 4 | PHASE2 | VERVE-102, VERVE-201 |
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE1 | Obicetrapib |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX310 |
| Esperion Therapeutics, Inc. | ESPR | 1 | - | Bempedoic acid+ Ezetimibe |
Vytorin + Niaspan refers to a combination treatment approach pairing Vytorin with Niaspan, studied for hypercholesterolemia. Vytorin is a small molecule therapy, and Niaspan is a niacin-based product. The combination has been evaluated in a Phase 1 drug interaction study in healthy subjects rather than as a single fixed-dose product.
Vytorin + Niaspan has been studied for hypercholesterolemia and hyperlipidemia, conditions involving elevated cholesterol and lipid levels in the blood. The clinical work on this combination focused on assessing how the two agents interact when used together in healthy adult subjects.
Organon & Co. (ticker: OGN) is the developer associated with Vytorin + Niaspan. Organon is the company linked to the clinical program evaluating this combination in hypercholesterolemia.
Vytorin + Niaspan is in Phase 1 development. The program's single recorded trial was a Phase 1 study, and it has been completed. The combination is investigational in this program and is not described as approved for the studied use.
Vytorin + Niaspan has been evaluated in one completed Phase 1 trial, NCT00652431, titled Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2). The study enrolled 18 healthy volunteers aged 18 years and older, was randomized, and used an active-controlled design without blinding.